On November 9, Meituan shares fell more than 5% in regular trading, trading at HK$76.35.

The clearest catalyst in current market information is a fresh broker action: Morgan Stanley downgraded both MEITUAN-W and PDD Holdings, providing a direct event-driven explanation for the stock’s intraday weakness.

Recent company updates had been mixed. In the past week, MEITUAN-W disclosed healthcare retail partnerships and industry initiatives, including a deeper strategic collaboration with Organon and the launch of a specialty-drug first-release alliance, while southbound funds had at times added to the stock. However, the latest and most time-relevant development is the downgrade published on November 9, which likely outweighed those earlier supportive items in today’s trading.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)